Refractory Bullous Pemphigoid Treated with Intermittent Dosing of Omalizumab
Malaysian Journal of Dermatology · 2025
DOI: 10.4103/mjd.mjd_24_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Malaysian Journal of Dermatology, 2025. Verfasst von Rebecca Kai Jan Choong und 3 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Bullous pemphigoid (BP) is a chronic autoimmune blistering disease that typically presents in older adults and is characterised by tense, pruritic blisters. Standard treatment includes corticosteroids and immunosuppressive agents, but refractory cases may necessitate adjunctive therapies, including biologics. We report a case of a 28-year-old male with refractory BP successfully managed with omalizumab, a monoclonal anti-immunoglobulin E antibody used in allergic conditions but showing promise as an adjunctive therapy for severe BP. This case illustrates the potential role of intermittent doses of subcutaneous omalizumab which is more cost-effective compared to continuous treatment, while still improving outcomes in patients with treatment-resistant BP.
Zitieren
APA
Choong, R. K. J., Faheem, N. A. A., Han, W. H., & Kwan, Z. (2025). Refractory Bullous Pemphigoid Treated with Intermittent Dosing of Omalizumab. Malaysian Journal of Dermatology. https://doi.org/10.4103/mjd.mjd_24_24
Vancouver
Choong RKJ, Faheem NAA, Han WH, Kwan Z. Refractory Bullous Pemphigoid Treated with Intermittent Dosing of Omalizumab. Malaysian Journal of Dermatology. 2025. doi:10.4103/mjd.mjd_24_24
BibTeX
@article{Choong2025,
author = {Choong, Rebecca Kai Jan and Faheem, Nik Aimee Azizah and Han, Winn Hui and Kwan, Zhenli},
title = {Refractory Bullous Pemphigoid Treated with Intermittent Dosing of Omalizumab},
journal = {Malaysian Journal of Dermatology},
year = {2025},
doi = {10.4103/mjd.mjd_24_24}
}
EUVIMED